Sponsor Preference of CRO Experience in Orphan Drug Trials
Despite the substantial difficulties associated with orphan drug trial recruitment, this segment of the drug development market is booming. By 2020, orphan drug sales are expected to make up 19% of prescription drug sales, excluding generics. In ISR’s Orphan Drug Market Dynamics and Patient Recruitment Best Practices report, ISR provides an overview of the orphan drug development market as well as how to best drive patient recruitment in an area of drug development in which drug developers do not want to be left behind.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025